Quantcast

Latest Avastin Stories

2009-04-22 07:00:00

Sutent/Taxol Will Earn Decision Resources' Clinical Gold Standard Status for the Indication by 2012, According to a New Report from Decision Resources WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in metastatic triple-negative breast cancer.

2009-04-08 07:00:00

Although Market Growth Will be Robust, Drug Development Has Been Disappointing in Recent Years, According to a New Report from Decision Resources WALTHAM, Mass., April 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the small-cell lung cancer drug market will more than double from just under $250 million in 2007 to more than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's...

2009-03-31 22:50:04

A U.S. Food and Drug Administration committee is recommending accelerated approval of the drug Avastin for treating brain cancer. Drug maker Genentech Inc.

2009-03-11 07:45:00

Unmet Need for Efficacious Therapies for Treating Patients With Mutated KRAS Genes Presents Significant Opportunity for Drug Developers, According to a New Report from Decision Resources WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of Roche/Genentech/Chugai's Avastin and Bristol-Myers Squibb/ImClone Systems*/Merck KGaA's Erbitux will drive the colorectal...

2009-03-10 07:00:00

However, Off-Label Use of Avastin Will Take Market Share Away from Lucentis from 2012 to 2017, According to a New Report from Decision Resources WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual 17 percent growth in the age-related macular degeneration (AMD) market through 2012 will be driven primarily by expanding use of Genentech/Novartis Ophthalmics'...

2009-03-09 07:00:00

A Drug That Improves Survival, When Added to Temodar/Temodal, Would Earn a 65 Percent Patient Share in the U.S.

2009-01-26 07:00:00

New data demonstrates that Angiolix has similar efficacy to Avastin alone and in combination with other chemotherapeutics, with potentially less side-effects; study validates results seen in Previous Breast Cancer Model DALLAS, Jan. 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.

2008-12-08 07:00:00

Generic Erosion Will Reduce Sales of Schering-Plough's Temodar/Temodal, the Current Market Leader, According to a New Report from Decision Resources WALTHAM, Mass., Dec.

2008-11-19 12:18:21

A drug touted as a safer, gentler way to treat cancer increases the risk of blood clots, a U.S.


Word of the Day
quilisma
  • In medieval musical notation, a sign or neume denoting a shake or trill.
The word 'quilisma' comes from a Greek word meaning 'a roll'.